Kepler Capital Keeps Their Hold Rating on GlaxoSmithKline (GSK)
In a report released on January 9, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...
Toggle3D.AI Options Issuance and CEO Change
TORONTO, ON / ACCESSWIRE / January 10, 2025 / Toggle3D.ai (the "Company") (OTCQB:TGGLF)(CSE:TGGL)(FSE:Q0C), a Nextech3d.ai ...
What went wrong for 23andMe
Biotech company 23andMe had a rough 2024, including a $30 million settlement payment after customer data was compromised.
Chronic Disease Management: Innovations in Therapeutics, Devices, and Global Markets
According to the latest study from BCC Research, "Chronic Disease Management: Therapeutics, Device Technologies, and Global ...
BCC Research LLC: Chronic Disease Management: Innovations in Therapeutics, Devices, and Global Markets
Emerging Technologies Revolutionize Chronic Disease Management: Insights into Bio-Wearables, Digital Therapeutics, and AI-Driven Solutions BOSTON, Jan. 10, 2025 /PRNewswire/ -- According ...
Indiatimes20h
GSK Pharma - GlaxoSmithKline Pharmaceuticals Share Price
GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...